NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced
that it has received notification that CE Mark approval has been granted
for LuViva® Advanced Cervical Scan, a non-invasive device
used to detect cervical disease that leads to cancer, instantly and at
the point of care.

The CE Mark is required to sell products in the 27 nations that comprise
the European Union (EU). There are about 146 million women who are
targeted by existing or planned cervical cancer screening programs in EU
member states, according to the European Cancer Observatory.

“The notification of CE Mark for LuViva is a significant milestone for
the company and allows us to begin our European launch later this year,
as planned,” said Mark L. Faupel, Ph.D., president and CEO of Guided
Therapeutics. “We believe that together with our distributors, we have a
tremendous opportunity to improve the detection of cervical disease,
reduce false positives and unnecessary biopsies, and provide significant
savings to healthcare systems throughout Europe.”

“Notification of the CE Mark and previously announced Health Canada
approval for LuViva further validates the product and our ability to
manufacture to the highest standards. We expect the CE Mark award will
generate more demand for the product and open opportunities in markets
outside the EU as well. In addition to the more than 20 countries
already covered by distribution agreements, we plan to expand our
network to additional countries in Europe, Latin America and Asia and
having the CE Mark should accelerate those efforts,” Dr. Faupel added.

Today's CE Mark notification is the first of two expected for LuViva. A
second CE Mark application is expected to be filed later this year to
comply with updated European medical device standards and to include
design improvements. The company also must continue to pass annual ISO
audits of its quality system in order to maintain the CE Mark on its
products. The company has passed two consecutive ISO audits, the last
being in January of 2012.

In addition to the CE Mark, LuViva has marketing approval from Health
Canada and remains under U.S. Food and Drug Administration premarket
approval review. Guided Therapeutics was awarded ISO 13485 certification
in January, 2011.

The study used to support LuViva’s CE Mark application was the
multi-center U.S. pivotal trial, in which 1,607 women at risk for
developing cervical disease were evaluated. In this patient population,
LuViva was able to detect cervical cancer up to two years earlier than
the Pap test, human papillomavirus (HPV) test, colposcopy and biopsy.
LuViva detected 86.3 percent of the cervical disease cases that had been
missed by Pap, HPV tests and biopsy. LuViva would have reduced the
number of unnecessary biopsies by about 40 percent. LuViva is initially
intended as a follow-up test after a positive Pap result.

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the
cervix with light and uses spectroscopy to measure how light interacts
with the cervical tissue. Spectroscopy identifies chemical and
structural indicators of precancer that may be below the surface of the
cervix or misdiagnosed as benign. This technique is called biophotonics.
Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory
analysis or a tissue sample, and is designed to provide results
immediately, which eliminates costly, painful and unnecessary testing.
LuViva is designed for use with women who have undergone initial
screening and are called back for follow up with a colposcopy
examination, which in many cases involves taking a biopsy of the cervix.
The device is used in conjunction with the LuViva® Cervical
Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is developing a
rapid and painless testing platform for the early detection of disease
based on its patented biophotonic technology that utilizes light to
detect disease at the cellular level. The Company’s first planned
product is the LuViva® Advanced Cervical Scan, a non-invasive
device used to detect cervical disease instantly and at the point of
care. In a multi-center clinical trial, with women at risk for cervical
disease, the technology was able to detect cervical cancer up to two
years earlier than conventional modalities, according to published
reports. Guided Therapeutics has also entered into a partnership with
Konica Minolta to develop a non-invasive test for Barrett’s Esophagus
using the technology platform. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva® Advanced
Cervical Scan is an investigational device and is limited by federal law
to investigational use. LuViva, the wave logo and "Early detection,
better outcomes" are registered trademarks owned by Guided Therapeutics,
Inc.

Forward-Looking Statements Disclaimer: A number of the matters and
subject areas discussed in this news release that are not historical or
current facts deal with potential future circumstances and developments.
The discussion of such matters and subject areas is qualified by the
inherent risks and uncertainties surrounding future expectations
generally and also may materially differ from Guided Therapeutics’
actual future experience involving any of or more of such matters and
subject areas. Such risks and uncertainties include those related to the
exchange offer, as described in the Offer to Exchange, as well as those
related to: the early stage of products in development, the uncertainty
of market acceptance of products, the uncertainty of development or
effectiveness of distribution channels, the intense competition in the
medical device industry, the uncertainty of capital to develop products,
the uncertainty of regulatory approval of products, dependence on
licensed intellectual property, as well as those that are more fully
described from time to time under the heading “Risk Factors” in Guided
Therapeutics’ reports filed with the SEC, including Guided Therapeutics’
Annual Report on Form 10-K for the fiscal year ended December 31, 2011,
and subsequent quarterly reports.